The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration

Gervasoni Cristina; Resnati Chiara; Formenti Tiziana; Fossati Alessandro; Minisci Davide; Meraviglia Paola; Cattaneo Dario

首页> 外文期刊>Antiviral therapy >The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration

【24h】

The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration

机译：药物 - 药物相互作用在临床实践中的相关性：伴随促进蛋白酶抑制剂加上α-1阻断给药的情况

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Antiviral therapy》 |2018年第5期|共3页
作者
Gervasoni Cristina; Resnati Chiara; Formenti Tiziana; Fossati Alessandro; Minisci Davide; Meraviglia Paola; Cattaneo Dario;
展开▼
作者单位

ASST Fatebenefratelli Sacco Univ Hosp Dept Infect Dis Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Dept Infect Dis Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Dept Infect Dis Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Unit Vasc Surg Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Dept Infect Dis Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Dept Infect Dis Milan Italy;

ASST Fatebenefratelli Sacco Univ Hosp Gest Ambulatoriale Politerapie GAP Outpatient Cli Milan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration [J] . Gervasoni Cristina, Resnati Chiara, Formenti Tiziana, Antiviral therapy . 2018,第5期

机译：药物 - 药物相互作用在临床实践中的相关性：伴随促进蛋白酶抑制剂加上α-1阻断给药的情况
2. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice [J] . Silvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, Journal of the International Aids Society . 2014,第4Suppla3期

机译：在临床实践中联合使用利托那韦增强蛋白酶抑制剂和替诺福韦停药率
3. Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma [J] . CoronaG., VaccherE., SpinaM., AIDS . 2013,第6期

机译：HIV霍奇金淋巴瘤患者中增强蛋白酶抑制剂和长春碱之间的潜在危险药物相互作用
4. Implementation of Clinical Decision Support Services to Detect Potential Drug-Drug Interaction Using Clinical Quality Language [C] . Binh-Phi Nguyen, Thomas Reese, Stefen Decker, MEDINFO . 2019

机译：临床决策支持服务的实施，以检测临床素质的潜在药物 - 药物互动
5. Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor, and Rosuvastatin. [D] . Samineni, Divya. 2011

机译：新型蛋白酶抑制剂Darunavir与瑞舒伐他汀之间药代动力学和药效动力学相互作用的临床前和临床研究。
6. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice [O] . Silvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, 2014

机译：在临床实践中联合使用利托那韦增强蛋白酶抑制剂和替诺福韦停药率
7. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice [O] . Silvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, 2014

机译：在临床实践中联合使用利托那韦增强的蛋白酶抑制剂和替诺福韦停药率

The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration

著录项

相似文献

相关主题

期刊订阅